Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Close this folderAnnex 1: Research proposal
View the documentI. Introduction
View the documentII. The Problem
View the documentIII. Research Question and Objectives of Proposed Study
View the documentIV. Study Approach
View the documentV. Anticipated Outcomes
View the documentVI. Methods
View the documentVII. Time Line and Resources
View the documentSelected References
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series
 

VII. Time Line and Resources

Project Work Plan

The project will have three phases: Planning, Research and Dissemination.

The planning phase will review the conceptual framework and finalize participating researchers, including senior people in the international health field who could serve as advisors of the project. To assure adequate consideration of private sector issues, advisors will also be sought, toward the end of the research phase, from major pharmaceutical companies in the United States, Europe, and Japan. A planning session of about 6 to 8 people was held at the Karolinska Institute in March 1994, to review research outlines and analytic approaches.

The research phase, as mentioned, will produce a series of country studies plus analytic essays that compare the performance of national pharmaceutical policies and examine policy-making processes at the national and international levels. Particular attention will be given to the mixture of public and private sectors and ways to resolve tensions between public and private interests.

The dissemination phase will begin with an international meeting, including representatives of the major organizations involved in pharmaceutical policy, with the objective of debating the project's research results. Efforts will be made to disseminate the conclusions to national policy-makers as well as decision-makers in international agencies.

Project Collaborators

The three main collaborators in the project are: the Department of International Health Care Research (IHCAR), Karolinska Institute; the Department of Population and International Health and Takemi Program in International Health, Harvard School of Public Health; and the Action Program on Essential Drugs, WHO. The project will be coordinated by Dr. Göran Tomson, MD, PhD, of Department of International Health Care Research (IHCAR) at the Karolinska Institute, assisted by Dr. Kris Weerasuriya, MD, PhD, Senior Lecturer, Department of Pharmacology, University of Colombo, Sri Lanka;

Professor Michael R. Reich, PhD, of the Department of Population and International Health, also Director of the Takemi Program in International Health at Harvard School of Public Health, assisted by Dr. Ramesh Govindaraj, MD, MS, Doctoral Candidate, Harvard School of Public Health; and Mrs Pascale Brudon-Jakobowicz, Scientist, APED, WHO. The coordinators represent the fields of health systems research, political science, health economics, and pharmacology.

Each coordinating institution is responsible for providing support in two or three of the eight selected countries: Sri Lanka, Vietnam, and Zambia will be supported by the Karolinska Institute; Colombia and India, by the Harvard School of Public Health; and Guinea, the Philippines, and Zimbabwe by the WHO. The collaborating institutions will be responsible for providing technical support and backstopping in the selected countries.

Each country research team should ideally include: an epidemiologist/statistician, an economist/social scientist, and a policy analyst, and possibly a computer analyst. However, it can be difficult in some countries to find such individuals; in this case the country coordinator will select the best available researchers. Each country's research team will be headed by a coordinator, who will have the overall responsibility for carrying out the field research in that country. The country coordinator will also be responsible for choosing the other members of the research team, and determining their individual responsibilities. The coordinator should have a good knowledge of the pharmaceutical sector in his/her country, and should possess the necessary disciplinary background, managerial and inter-personal skills, and adequate time to undertake project responsibilities.

The project will begin in Fall, 1993, for a two-year period, with a planning session in March, 1994, and a major international meeting to disseminate findings at the end of 1995. The project schedule is presented below.

Project Schedule

Fall, 1993

- Preparatory meeting among project coordinators, at the Harvard School of Public Health

March, 1994

- Planning session in Stockholm to review the conceptual framework and select the participating countries

June, 1994

- Indicators to be finalized by mid-June. Four background documents (background paper, project protocol, indicator manual and mapping manual) to be completed by mid-June. Country coordinators to be identified by the end of June.

July, 1994

- An official letter of invitation to join the project to be sent to each country team, along with copies of background documents, etc. by end of July.

Oct., 1994

- Round 1 of Group Evaluation: Planning session of country coordinators and international coordinators in Geneva, to review research methods and initiate research project.

Nov., 1994-Feb., 1995

- Data collection and analysis of Indicator surveys to be undertaken between October, 1994 - Feb., 1995. A country visit by a member of the coordinating institution will be undertaken in Jan-Feb., 1995.

March-June, 1995

- Political mapping of the process of NDP formulation and implementation to be carried out in participating countries

July, 1995

- Round 2 of Group Evaluation: International meeting of research team representatives in a developing country to discuss research findings and policy implications and prepare for next round of mapping

July, 1995 - Nov., 1995

- Second round of political mapping in selected countries, focusing on specific questions

Dec., 1995

- Major international meeting to discuss full research findings, and disseminate the results

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014